Share on StockTwits

Equities researchers at Robert W. Baird increased their price objective on shares of InterMune (NASDAQ:ITMN) from $44.00 to $50.00 in a research report issued on Thursday. Robert W. Baird’s price target would indicate a potential upside of 13.02% from the company’s current price.

Shares of InterMune (NASDAQ:ITMN) opened at 44.24 on Thursday. InterMune has a one year low of $10.95 and a one year high of $47.72. The stock’s 50-day moving average is $44.1 and its 200-day moving average is $33.46. The company’s market cap is $4.375 billion.

InterMune (NASDAQ:ITMN) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.72) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.56) by $0.16. The company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $33.96 million. During the same quarter in the prior year, the company posted ($0.77) earnings per share. The company’s quarterly revenue was up 141.2% on a year-over-year basis. Analysts expect that InterMune will post $-2.32 EPS for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of InterMune from $22.00 to $25.00 in a research note on Thursday. Separately, analysts at Oppenheimer raised their price target on shares of InterMune from $42.00 to $50.00 in a research note on Monday, June 16th. They now have an “outperform” rating on the stock. Finally, analysts at JMP Securities raised their price target on shares of InterMune from $48.00 to $55.00 in a research note on Thursday, June 12th. They now have a “market outperform” rating on the stock. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $44.15.

InterMune, Inc (NASDAQ:ITMN) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.